Search Count: 5
All
Selected
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Resolution:1.37 Å Release Date: 2025-08-20 Classification: HYDROLASE/INHIBOTOR Ligands: A1L7M |
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Resolution:1.89 Å Release Date: 2025-08-20 Classification: HYDROLASE/INHIBITOR |
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Resolution:1.50 Å Release Date: 2025-08-20 Classification: HYDROLASE/INHIBITOR |
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Resolution:1.47 Å Release Date: 2025-08-20 Classification: HYDROLASE/INHIBITOR Ligands: A1L7M |
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Resolution:2.20 Å Release Date: 2025-08-20 Classification: HYDROLASE/INHIBITOR Ligands: A1L7M |